Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078003 | 0.87 | MET (0.49) | METRPS6KA3ALDH1A1KDM4ELMNA | |
| SCHEMBL1583435 | 0.86 | MET (0.62) | METRPS6KA3SMN1; SMN2 | |
| SCHEMBL1079941 | 0.85 | MET (0.53) | METALDH1A1SMN1; SMN2 | |
| SCHEMBL1583727 | 0.83 | MET (0.71) | METRPS6KA3ALDH1A1KDM4EMAPT | |
| SCHEMBL11938839 | 0.82 | MET (0.59) | METALDH1A1KDM4E | |
| SCHEMBL1583574 | 0.81 | MET (0.56) | METRPS6KA3 | |
| SCHEMBL12808129 | 0.80 | MET (0.55) | METRPS6KA3ALDH1A1KDM4EMAPT | |
| SCHEMBL1983683 | 0.78 | MET (0.61) | METRPS6KA3ALDH1A1KDM4EMAPT | |
| SCHEMBL1993082 | 0.78 | MET (0.62) | METRPS6KA3ALDH1A1 | |
| SCHEMBL12595668 | 0.77 | MET (0.56) | METRPS6KA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2451817-B1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2451817-B1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| EP-2451817-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003604-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003604-A1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BMX, MET, ABL1 | MET 2/4885RPS6KA3 1483/4885ALDH1A1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.